For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

A phase 2 trial tested the efficacy of local stereotactic body radiation therapy (SBRT) use after radical prostatectomy.

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

Researchers report longer progression-free survival when Lutetium-177 was combined with standard radiotherapy for limited ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT) ...

A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to ...

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy. The first patient has been enrolled in the phase ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...